Verastem (VSTM) Assets Average (2012 - 2026)
Verastem (VSTM) posted quarterly Assets Average of $237.1 million for Q1 2026, up 103.33% year-over-year from $116.6 million in Q1 2025, and up 12.04% quarter-over-quarter from $211.6 million in Q4 2025.
Analysis
Verastem (VSTM) Assets Average (2012 - 2026) Analysis & Trends
Verastem's Assets Average history runs 15 years deep, the most recent figure standing at $237.1 million for Q1 2026.
- In Q1 2026, Assets Average rose 103.33% year-over-year to $237.1 million; the TTM figure through Mar 2026 stood at $237.1 million (up 103.33% YoY), while the FY2025 annual figure was $174.0 million, up 38.5% from the prior year.
- Assets Average for Q1 2026 stood at $237.1 million, up from $211.6 million in the prior quarter.
- The five-year high for Assets Average was $237.1 million in Q1 2026, with the low at $103.1 million in Q4 2022.
- The 5-year median for Assets Average is $116.6 million (2025), against an average of $143.4 million.
- The sharpest annual moves came in 2024 and 2026: Assets Average slumped 36.91% in 2024, then jumped 103.33% in 2026.
- Verastem's Assets Average stood at $103.1 million in 2022, then soared by 58.08% to $162.9 million in 2023, then plunged by 30.06% to $114.0 million in 2024, then soared by 85.72% to $211.6 million in 2025, then increased by 12.04% to $237.1 million in 2026.
- Business Quant data shows VSTM's Assets Average at $237.1 million in Q1 2026, $211.6 million in Q4 2025, and $186.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 217.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 217.16 Mn |
| Mar 31, 2026 | 237.13 Mn |
| Dec 31, 2025 | 211.65 Mn |
| Sep 30, 2025 | 186.56 Mn |
| Jun 30, 2025 | 163.98 Mn |
| Mar 31, 2025 | 116.62 Mn |
| Dec 31, 2024 | 113.96 Mn |
| Sep 30, 2024 | 116.06 Mn |
| Jun 30, 2024 | 114.64 Mn |
| Mar 31, 2024 | 136.63 Mn |
| Dec 31, 2023 | 162.94 Mn |
| Sep 30, 2023 | 183.96 Mn |
| Jun 30, 2023 | 156.32 Mn |
| Mar 31, 2023 | 107.96 Mn |
| Dec 31, 2022 | 103.07 Mn |
| Sep 30, 2022 | 105.75 Mn |
| Jun 30, 2022 | 108.28 Mn |
| Mar 31, 2022 | 112.41 Mn |
| Dec 31, 2021 | 110.27 Mn |
| Sep 30, 2021 | 117.88 Mn |